The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
Open accessAbstract
BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both insulin glargine U100 and insulin degludec have demonstrated cardiovascular safety in dedicated CVOTs (207,208).”
From Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022) · cites this paper as [208]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are a number of other trials regarding cardiovascular outcomes in high-risk cohorts of patients with type 2 diabetes in which similar magnitude effects on glycemic control have been shown but without significant benefits with respect to rates of cardiovascular events or death.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“ORIGIN reported a 1.6 kg gain over 6 years with insulin glargine [46].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [46]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Modest survival benefits also have been reported for breast, ovarian, endometrial, prostate, lung, kidney, liver, and earlier stage pancreatic cancers.1791–1800”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1800]
Experimental — accuracy not yet measuredIn the citing paper
“The following drug classes were excluded due to lack of current evidence of efficacy in cardiovascular outcome trials: dipeptidyl peptidase-4 inhibitors,19 sulfonylureas,20 and insulin.21,22”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [21]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“It is associated with a lower risk of death and HF hospitalization compared with insulin and sulphonylureas in observational studies, though dedicated randomized, controlled, CVOTs evaluating safety and efficacy of metformin have not been conducted.[555][556][557]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [555]
In the citing paper
“These trials have more or less uniformly demonstrated a benefit, with lifestyle more efficacious than all medications with the exception of the thiazolidinediones140–152.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [146]
In the citing paper
“In the only RCT of insulin vs. placebo [ORIGIN, 12 537 people with CV risk factors plus impaired fasting glucose, impaired glucose tolerance, or T2DM (i.e.not in patients with HF)], insulin was not associated with higher rates of HF hospitalization than placebo.187”
From Type 2 diabetes mellitus and heart failure: A position statement from the Heart Failure Association of the European Society of Cardiology (2018) · cites this paper as [187]
In the citing paper
“Lowering glucose without addressing the vascular effects of insulin resistance may be insufficient to reduce risk of cardiovascular events.”
From The Vasculature in Prediabetes (2018) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death
The Emerging Risk Factors Collaboration (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1008862 · Cited by 2,726
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults
Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., Coresh, J., & Brancati, F. L. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908359 · Cited by 1,544
Flagged first, then by citations
Research works printed but not linked: 1
- Gerstein H, 2008, Am Heart J, 155, 26
Cited by
Sorted by citations
Items 301–400 of 999
Heart Failure Considerations of Antihyperglycemic Medications for Type 2 Diabetes
Standl, E., Schnell, O., & McGuire, D. K. (2016) · Circulation Research · doi:10.1161/circresaha.116.306924 · Cited by 60
Heart Failure: a Major Cardiovascular Complication of Diabetes Mellitus
Bahtiyar, G., Gutterman, D. D., & Lebovitz, H. E. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0809-4 · Cited by 60
The heart failure burden of type 2 diabetes mellitus—a review of pathophysiology and interventions
Ofstad, A. P., Atar, D., Gullestad, L. L., Langslet, G., & Johansen, O. E. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9685-0 · Cited by 59
Lamos, E. M., Younk, L. M., & Davis, S. N. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.791282 · Cited by 58
Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes
Patti, A. M., Rizvi, A. A., Giglio, R. V., Stoian, A. P., Ligi, D., & Mannello, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040912 · Cited by 61
Yajnik, C. S., Katre, P. A., Joshi, S. M., Kumaran, K., Bhat, D., Lubree, H., MEMANE, N. S., Kinare, A. S., Pandit, A. N., Bhave, S. A., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3602-z · Cited by 62
Type 2 diabetes and cardiovascular disease: what next?
Joseph, J. J., & Golden, S. H. (2014) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000044 · Cited by 57
Bertoluci, M. C., Moreira, R. O., Faludi, A. Á., Izar, M. C. D. O., Schaan, B. D., Valério, C. M., Bertolami, M. C., Chacra, A. P. M., Malachias, M. V. B., Vencio, S. A. C., et al. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0251-z · Cited by 59
Greene, S. J., Vaduganathan, M., Khan, M. S., Bakris, G. L., Weir, M. R., Seltzer, J. H., Sattar, N., McGuire, D. K., Januzzi, J. L., Stockbridge, N., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.01.047 · Cited by 56
Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial
Holman, R. R., Bethel, M. A., Chan, J. C. N., Chiasson, J., Doran, Z., Ge, J., Gerstein, H. C., Huo, Y., McMurray, J. J. V., Rydén, L., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.021 · Cited by 56
Nusca, A., Tuccinardi, D., Pieralice, S., Giannone, S., Carpenito, M., Monte, L., Watanabe, M., Cavallari, I., Maddaloni, E., Ussia, G. P., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.670155 · Cited by 60
Lin, C., Huang, H., Chu, F.-Y., Fan, H., Chen, H.-A., Chu, D., Wu, L., Wang, C., Chen, W., Lin, S., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125421 · Cited by 56
Dysglycaemia, vasculopenia, and the chronic consequences of diabetes
Gerstein, H. C., & Werstuck, G. H. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70025-1 · Cited by 58
Pathogenesis, Clinical Features and Treatment of Diabetic Cardiomyopathy
Alonso, N., Moliner, P., & Mauricio, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/5584_2017_105 · Cited by 57
Gu, Y., Wang, C., Zheng, Y., Hou, X., Mo, Y., Yu, W., Zhang, L., Hu, C., Nan, H., Chen, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053411 · Cited by 55
On the potential of acarbose to reduce cardiovascular disease
Standl, E., Theodorakis, M. J., Erbach, M., Schnell, O., & Tuomilehto, J. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-81 · Cited by 58
Approach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 55
Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials
Erpeldinger, S., Rehman, M. B., Berkhout, C., Pigache, C., Zerbib, Y., Regnault, F., Guérin, É., Supper, I., Cornu, C., Kassaï, B., et al. (2016) · BMC Endocrine Disorders · doi:10.1186/s12902-016-0120-z · Cited by 60
Faludi, A., Izar, M., Saraiva, J., Bianco, H. T., Chacra, A., Bertoluci, M., Moreira, R., Turatti, L., Bertolami, A., Sulzbach, M. L., et al. (2017) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20170188 · Cited by 61
Shi, W., Zhang, W., Zhang, D., Ren, G., Wang, P., Gao, L., Chen, H., & Ding, C. (2021) · Heart Rhythm · doi:10.1016/j.hrthm.2021.03.007 · Cited by 54
A1C targets should be personalized to maximize benefits while limiting risks
Riddle, M. C., Gerstein, H. C., Holman, R. R., Inzucchi, S. E., Zinman, B., Zoungas, S., & Cefalu, W. T. (2018) · Diabetes Care · doi:10.2337/dci18-0018 · Cited by 54
Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup‐Linde, J., Bazelier, M. T., Bruin, M. L. D., de Boer, A., Siezen, C. L. E., van de Water, B., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0611-2 · Cited by 54
Effect of glucose-lowering therapies on heart failure
Nassif, M. E., & Kosiborod, M. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.211 · Cited by 54
Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials
Bailey, C. J., & Marx, N. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13492 · Cited by 56
Cardiovascular Risk Stratification and Management in Pre-Diabetes
Færch, K., Vistisen, D., Johansen, N. B., & Jørgensen, M. E. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0493-1 · Cited by 60
Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?
Giorgino, F., Home, P., & Tuomilehto, J. O. (2016) · Diabetes Care · doi:10.2337/dcs15-3023 · Cited by 55
Park, K., Li, Q., Evcimen, N. D., Rask‐Madsen, C., Maeda, Y., Maddaloni, E., Yokomizo, H., Shinjo, T., St-Louis, R., Fu, J., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310291 · Cited by 54
Diabetes and Cancer: 5 Years Into the Recent Controversy
Badrick, E., & Renehan, A. G. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.032 · Cited by 53
Vallarino, C. R., Perez, A., Fusco, G., Liang, H., Bron, M., Manne, S., Joseph, G. L., & Yu, S. S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0106-9 · Cited by 53
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
Avogaro, A., Fadini, G. P., Sesti, G., Bonora, E., & Prato, S. D. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0431-4 · Cited by 53
Benefits of timely basal insulin control in patients with type 2 diabetes
Lovre, D., & Fonseca, V. A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.11.018 · Cited by 55
Lind, M., Tuomilehto, J., Uusitupa, M. I. J., Nerman, O., Eriksson, J. G., Ilanne‐Parikka, P., Keinanen-Kiukaanniemi, S. M., Peltonen, M., Pivodic, A., & Lindström, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109506 · Cited by 55
The ORIGIN trial investigators, Gilbert, R. E., Mann, J. F. E., Hanefeld, M., Spinas, G. A., Bosch, J., Yusuf, S., & Gerstein, H. C. (2014) · Diabetologia · doi:10.1007/s00125-014-3238-4 · Cited by 55
Self-citationDiabetes Mellitus and Heart Failure
Tousoulis, D., Oikonomou, E. K., Siasos, G., & Stefanadis, C. (2014) · European Cardiology Review · doi:10.15420/ecr.2014.9.1.37 · Cited by 55
Merino, J., Leong, A., Posner, D. C., Porneala, B., Masana, L., Dupuis, J., & Florez, J. C. (2017) · Diabetes Care · doi:10.2337/dc16-2625 · Cited by 52
Metformin Should Not Be Used to Treat Prediabetes
Davidson, M. B. (2020) · Diabetes Care · doi:10.2337/dc19-2221 · Cited by 52
Cersosimo, E., Johnson, E. L., Chovanes, C., & Skolnik, N. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13108 · Cited by 52
Updates on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0610-y · Cited by 52
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2026
Bajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s003 · Cited by 72
Early therapy for type 2 diabetes in China
Yang, W., & Weng, J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70136-6 · Cited by 53
Insulin and atherosclerosis: How are they related?
Monnier, L., Markolf Hanefeld, E., Schnell, O., Colette, C., & Owens, D. R. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.02.001 · Cited by 52
Sex-specific differences in diabetes prevention: a systematic review and meta-analysis
Glechner, A., Harreiter, J., Gartlehner, G., Rohleder, S., Kautzky, A., Tuomilehto, J. O., Noord, M. V., Kaminski-Hartenthaler, A., & Kautzky‐Willer, A. (2014) · Diabetologia · doi:10.1007/s00125-014-3439-x · Cited by 56
2020 vision – An overview of prospects for diabetes management and prevention in the next decade
Wang, C., Neil, D. L., & Home, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.06.007 · Cited by 51
Nyström, T., Bodegård, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.12.004 · Cited by 52
Evaluation and Treatment of Prediabetes in Youth
Magge, S. N., Silverstein, J. H., Elder, D. A., Nadeau, K. J., & Hannon, T. S. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.12.061 · Cited by 59
Bragg, F., Li, L., Bennett, D., Yu, C., Lewington, S., Bian, Z., Yang, L., Chen, J., Chen, Y., Collins, R., et al. (2016) · JAMA Cardiology · doi:10.1001/jamacardio.2016.1702 · Cited by 49
Mechanisms linking empagliflozin to cardiovascular and renal protection
Filardi, P. P., Avogaro, A., Bonora, E., Colivicchi, F., Fioretto, P., Maggioni, A. P., Sesti, G., & Ferrannini, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.03.089 · Cited by 51
Documento de abordaje integral de la diabetes tipo 2
Reyes‐García, R., Moreno, Ó., Pérez, C. T., Fernández‐García, D., Bellido, V., Casares, M. L. D. L. T., Rozas-Moreno, P., Fernández‐García, J. C., Martínez, A. M., Escalada, J., et al. (2019) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2018.10.010 · Cited by 54
Scheen, A. J. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.12.005 · Cited by 50
Intensive glycaemic control and cognitive decline in patients with type 2 diabetes: a meta-analysis
Tuligenga, R. H. (2015) · Endocrine Connections · doi:10.1530/ec-15-0004 · Cited by 49
Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
Stürmer, T., Marquis, M. A., Zhou, H., Meigs, J. B., Lim, S. K., Blonde, L., MacDonald, E. B., Wang, R., LaVange, L. M., Pate, V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0263 · Cited by 48
Impact of hyperglycemia on the efficacy of chemotherapy—A systematic review of preclinical studies
Gerards, M. C., Velden, D. L. V. D., Baars, J. W., Brandjes, D. P. M., Hoekstra, J. B. L., Vriesendorp, T. M., & Gerdes, V. E. A. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.007 · Cited by 49
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 51
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update
(2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.02.006 · Cited by 49
Associations between Diabetes Mellitus and Selected Cancers
Pliszka, M., & Szablewski, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137476 · Cited by 53
Hyperglycemia and Vascular Metabolic Memory: Truth or Fiction?
Bianchi, C., Miccoli, R., & Prato, S. D. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0371-2 · Cited by 47
Insulin therapy, weight gain and prognosis
Hodish, I. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13367 · Cited by 48
The limitations of observation studies for decision making regarding drugs efficacy and safety
Gueyffier, F., & Cucherat, M. (2018) · Therapies · doi:10.1016/j.therap.2018.11.001 · Cited by 50
Ceriello, A., de Valk, H. W., Guerci, B., Haak, T., Owens, D. R., Canobbio, M., Fritzen, K., Stautner, C., & Schnell, O. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108053 · Cited by 50
Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
Dąbrowski, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041680 · Cited by 50
JCS 2023 Guideline on the Primary Prevention of Coronary Artery Disease
Fujiyoshi, A., Kohsaka, S., Hata, J., Hara, M., Kai, H., Masuda, D., Miyamatsu, N., Nishio, Y., Ogura, M., Sata, M., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0285 · Cited by 55
Lonn, E., Bosch, J., Díaz, R., López-Jaramillo, P. A., Ramachandran, A., Hâncu, N., Hanefeld, M., Krum, H., Rydén, L., Smith, S. L., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2129 · Cited by 48
Ioannidis, J. P. A., Zhou, Y., Chang, C. Q., Schully, S. D., Khoury, M. J., & Freedman, A. N. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt372 · Cited by 46
Mosenzon, O., & Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2007 · Cited by 48
Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes
Madenidou, A., Paschos, P., Karagiannis, T., Katsoula, A., Athanasiadou, E. A., Kitsios, K., Bekiari, E., Matthews, D. R., & Τσάπας, Α. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0443 · Cited by 47
Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes
Perreault, L., Rodbard, H. W., Valentine, V., & Johnson, E. L. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0868-9 · Cited by 47
Schnell, O., Standl, E., Catrinoiu, D., Itzhak, B., Lalic, N. M., Rahelić, D., Škrha, J., Valensi, P. E., & Ceriello, A. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0822-4 · Cited by 47
Sam, S., Edelstein, S. L., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Ehrmann, D. A., Hannon, T. S., Tjaden, A. H., Kahn, S. E., et al. (2021) · Diabetes Care · doi:10.2337/dc21-0027 · Cited by 49
Diabetes and cancer: Epidemiology and potential mechanisms
Joost, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114550813 · Cited by 45
Keating, G. M. (2012) · Drugs · doi:10.2165/11470200-000000000-00000 · Cited by 47
Ekström, N., Svensson, A., Miftaraj, M., Franzén, S., Zethelius, B., Eliasson, B., & Guðbjörnsdóttir, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12704 · Cited by 47
Verma, N., Liu, M., Ly, H., Loria, A. S., Campbell, K. S., Bush, H., Kern, P. A., José, P. A., Taegtmeyer, H., Bers, D. M., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.07.028 · Cited by 46
Hypoglycaemia and cardiac arrhythmias in diabetes
Andersen, A., Jørgensen, P. G., Knop, F. K., & Vilsbøll, T. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820911803 · Cited by 48
Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis
Petrelli, F., Ghidini, M., Rausa, E., Ghidini, A., Cabiddu, M., Borgonovo, K., Ghilardi, M., Parati, M. C., Pietrantonio, F., Sganzerla, P., et al. (2020) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2020.06.009 · Cited by 46
Do the SGLT-2 Inhibitors Offer More than Hypoglycemic Activity?
Flores, E., Santos‐Gallego, C. G., Mejia, N. M. D., & Badimón, J. J. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6786-x · Cited by 44
Intensive Glucose Regulation in Hyperglycemic Acute Coronary Syndrome
de Mulder, M., Umans, V. A. W. M., Cornel, J. H., van der Zant, F. M., Stam, F., Oemrawsingh, R. M., Akkerhuis, K. M., & Boersma, E. H. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.10074 · Cited by 46
Risk factors for cancer development in type 2 diabetes: A retrospective case-control study
Dąbrowski, M., Szymańska‐Garbacz, E., Miszczyszyn, Z., Dereziński, T., & Czupryniak, L. (2016) · BMC Cancer · doi:10.1186/s12885-016-2836-6 · Cited by 45
Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions
Perreault, L., Vincent, L., Neumiller, J. J., & Cavaiola, T. S. (2019) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2019.03.180162 · Cited by 45
Andersen, A., Bagger, J. I., Sørensen, S. K., BALDASSARRE, M. P. A., Pedersen‐Bjergaard, U., Forman, J. L., Gislason, G., Lindhardt, T. B., Knop, F. K., & Vilsbøll, T. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01425-0 · Cited by 45
Pistrosch, F., Köhler, C. U., Schäper, F., Landgraf, W., Forst, T. M., & Hanefeld, M. (2013) · Acta Diabetologica · doi:10.1007/s00592-012-0451-9 · Cited by 48
Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0051-1 · Cited by 43
Prediabetes and risk of diabetes and associated complications
Abdul‐Ghani, M. A., DeFronzo, R. A., & Jayyousi, A. (2016) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000307 · Cited by 44
Understanding the impact of hypoglycemia on the cardiovascular system
Davis, I., Ahmadizadeh, I., Randell, J., Younk, L. M., & Davis, S. N. (2016) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2017.1275960 · Cited by 44
Home, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2002 · Cited by 44
Hirshberg, B., & Katz, A. (2013) · Diabetes Care · doi:10.2337/dcs13-2041 · Cited by 44
Diabetes mellitus and atrial fibrillation-from pathophysiology to treatment
Leopoulou, M., Theofilis, P., Kordalis, A., Παπαγεωργίου, Ν., Sagris, Μ., Oikonomou, E. K., & Tousoulis, D. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i5.512 · Cited by 47
The Impact of Hypoglycemia on the Cardiovascular System
Yang, S., Park, K., & Zhou, Y.-J. (2015) · Angiology · doi:10.1177/0003319715623400 · Cited by 45
Echocardiographic feature of diabetic cardiomyopathy: where are we now?
Negishi, K. (2018) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2018.01.03 · Cited by 43
Predicting Cardiovascular Risk in Type 2 Diabetes: the Heterogeneity Challenges
Gore, M. O., McGuire, D. K., Lingvay, I., & Rosenstock, J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0607-7 · Cited by 45
2022 Guidelines on the management of patients with diabetes. A position of Diabetes Poland
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2022) · Current Topics in Diabetes · doi:10.5114/ctd/146259 · Cited by 45
Kim, S. G., Kim, N. H., Ku, B. J., Shon, H. S., Kim, D. M., Park, T. S., Kim, Y., Kim, I. J., & Cho, Y. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12581 · Cited by 44
Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence
Leonard, C. E., Hennessy, S., Han, X., Siscovick, D. S., Flory, J., & Deo, R. (2017) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2017.04.003 · Cited by 43
Cardiovascular disease prevention strategies for type 2 diabetes mellitus
Katsiki, N., Purrello, F., Tsioufis, C. P., & Mikhailidis, D. P. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1351946 · Cited by 42
Linking type 2 diabetes and gynecological cancer: an introductory overview
Anastasi, E., Filardi, T., Tartaglione, S., Lenzi, A., Angeloni, A., & Morano, S. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2017-0982 · Cited by 46
Carbone, S., Dixon, D. L., Buckley, L. F., & Abbate, A. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2018.07.018 · Cited by 44
Changing patterns of sexually transmitted infections in India.
Sharma, V., & Khandpur, S. (2004) · PubMed · Cited by 42
Sinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 45
Alvarez, C., Lingvay, I., Vuylsteke, V., Koffarnus, R. L., & McGuire, D. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.143 · Cited by 42
Prevention of type 2 diabetes mellitus: is it feasible?
Palermo, A., Maggi, D., Maurizi, A. R., Pozzilli, P., & Buzzetti, R. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2513 · Cited by 44
Kuhl, J., Sartipy, U., Eliasson, B., Nyström, T., & Holzmann, M. J. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.09.008 · Cited by 40
Metadata
- Authors
- The ORIGIN Trial Investigators
- Affiliations
- Population Health Research Institute (CA)
- Corresponding author
- The ORIGIN Trial Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-07-26
- Volume
- 367
- Issue
- 4
- Pages
- 319-328
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975663485
- Semantic Scholar
- 695c6a8e398d66ae418b143a3491ad91d28443bb
- Cited by
- 1,636
- References
- 29
- Citations by year
- 2026: 34 · 2025: 41 · 2024: 76 · 2023: 86 · 2022: 82 · 2021: 108 · 2020: 101 · 2019: 139 · 2018: 155 · 2017: 152 · 2016: 155 · 2015: 132 · 2014: 168 · 2013: 147 · 2012: 53
- FWCI
- 128.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- IRIS (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- University of Oxford
- AFA Försäkring
- Hjärt-Lungfonden
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- basal insulin, insulin glargine, impaired fasting glucose, impaired glucose tolerance, type 2 diabetes, cardiovascular outcomes, myocardial infarction, stroke, heart failure, omega-3 fatty acids, hypoglycemia, weight gain, cancer risk, microvascular outcomes, cardiovascular risk factors, revascularization, hospitalization, new-onset diabetes
- MeSH terms
- Insulin Glargine, Aged, Blood Glucose, Cardiovascular Diseases, Cholesterol, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Fasting, Female, Follow-Up Studies, Hospitalization, Humans, Hypoglycemia, Hypoglycemic Agents, Male, Middle Aged, Triglycerides, Fatty Acids, Omega-3, Incidence, Proportional Hazards Models, Glucose Intolerance, Insulin, Long-Acting, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
